TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04562090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: Mirabegron was administered as single oral dose of 25 mg or 50 mg sustained-release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: Mirabegron was administered as single oral dose of 25 mg or 50 mg sustained-release tablet
Study: NCT06642688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sacroiliac Joint Manipulation
Description: The patient was asked to tie his arms while he was in the side lying position. The patient's upper knee was flexed and positioned such that it was placed in the popliteal fossa of the lower knee, while the lower knee was in full extension. Pushing maneuver was performed with HVLA from posterior to anterior and from medial to lateral with pelvic rotation. The contact point of the sacroiliac joint was PSIS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Spine Manipulation
Description: Cervical SM was applied supine to restrictions found on motion palpation, according to the technique described by Bergmann and Peterson28 The participant's head and neck were simultaneously rotated and laterally flexed over the contact point-specifically, the posterior supramastoid groove or zygomatic arch (C0-C1), the posterior aspect of the transverse process (C1-C2), or the posterior articular pillar of superior vertebrae (C2-C7) -to the end of passive ROM. Thereafter, a high-velocity, low-amplitude thrust was delivered in the direction of restricted movement. Participants with more ROM restriction in the lateral plane were given more lateral-to-medial directed thrusts; participants with more restriction in rotation were given thrusts in the direction of restricted axial rotation; and participants with more restriction in extension were given more anteriorly directed thrusts.
Study: NCT05384223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RRFT (Risk Reduction through Family Therapy)
Description: RRFT is an adaptation and integration of existing empirically-supported interventions with similar theoretical rationales targeting similar populations, particularly Multisystemic Therapy principles (MST)for adolescent SUP and Trauma Focused-Cognitive Behavioral Therapy (TF-CBT) components for PTSD in youth. RRFT consists of seven primary components: Psychoeducation and Engagement, Coping, Family Communication, Substance Use, PTSD, Healthy Dating and Sexual Decision-Making, and Revictimization Risk Reduction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ENCOMPASS (Integrated Treatment for Adolescents and Young Adults)
Description: Encompass is currently a research to practice treatment for adolescents with co-occurring substance use disorders and mental health problems and is used as the standard treatment in the target study settings.
Study: NCT06171802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: 10 mg empagliflozin daily for six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once daily for six months
Study: NCT04511468

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc, Chromium, Vitamin C, and Copper Supplementation
Description: Combination of mineral and vitamin supplementation that consist of Zinc, Chromium, Vitamin C, and Copper

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard healthy lifestyle intervention
Description: Standard healthy lifestyle intervention will follow the Guidelines on the Management and Prevention of Prediabetes by the Indonesian Ministry of Healthy and the Indonesian Diabetes Association.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard healthy lifestyle intervention
Description: Standard healthy lifestyle intervention will follow the Guidelines on the Management and Prevention of Prediabetes by the Indonesian Ministry of Healthy and the Indonesian Diabetes Association.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with inactive ingredients
Study: NCT05013905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRA023 IV
Description: PRA023 administered at timepoints as directed by the protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Companion diagnostic (CDx)
Description: CDx+ or CDx-
Study: NCT05852470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon Vivity/Vivity Toric Extended Vision IOL
Description: Extended vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clareon Monofocal/Clareon Toric IOL
Description: Single vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
Study: NCT06566768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days
Study: NCT06528184

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Self-sampled HPV DNA testing
Description: Participants will be offered HPV DNA testing done through self-sampling (using self-sampling HPV DNA kits to obtain a mid-vaginal swab)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinician-sampled HPV DNA test
Description: Participants will be offered HPV DNA testing through clinician sampling (clinician-sampling (speculum examination by a nurse to obtain a cervical swab)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Clinician-sampled HPV DNA test
Description: Participants will be offered HPV DNA testing through clinician sampling (clinician-sampling (speculum examination by a nurse to obtain a cervical swab)
Study: NCT06514443

Intervention type: OTHER
Intervention: survey
Description: survey exploring barriers and faciltiators for physical activity

Intervention type: OTHER
Intervention: survey
Description: survey exploring barriers and faciltiators for physical activity
Study: NCT06074757

Intervention type: DRUG
Group type: OTHER
Intervention: Fulvestrant injection
Description: phosphate ester of fulvestrant for test arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant injection
Description: phosphate ester of fulvestrant for test arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant injection
Description: phosphate ester of fulvestrant for test arm
Study: NCT05912452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percussion Massage Therapy
Description: Individuals who receive percussion massage therapy will be treated with a 5-minute medium-frequency percussion massage on the deltoid muscle group every other day. Percussion massage therapy will be applied in a total of 10 sessions and will be completed in 20 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: the Kinesiotape group; Kinesiotape banding will be done with 25% tension by applying a Y band to the deltoid muscle group. After the application, the Kinesio band will stay on the participant for 2 days. The next day, the participant will rest. This cycle will be repeated for 20 days.
Study: NCT06074757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant injection
Description: phosphate ester of fulvestrant for test arm
Study: NCT05912452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Description: Dynamic stretching exercises will be applied to the shoulder flexor and abductor muscle groups in the Dynamic Stretching Group with 10 repetitions. As in percussion massage therapy, these exercises will be performed under the supervision of a physiotherapist every other day. The application will continue for 20 days.
Study: NCT06094855

Intervention type: OTHER
Intervention: 20 minutes of biking on a stationary recumbent bicycle with and without a cooling vest
Description: 2 bouts of 20 minutes of pedaling on a stationary recumbent bicycle, 1-2 weeks apart. Subjects will be cooled for one of the bouts and uncooled for the other.
Study: NCT06468930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level light therapy (LLLT)
Description: LLLT therapy will be delivered using the Light Modulation® special facial mask (Espansione Marketing S.p.A., Bologna, Italy) which will be placed on the participant's face for 15 minutes. The mask has the shape of a half-face and will emit a red light in an LED system. The device has an emission power of 100 The mask has the shape of a half-face and will emit a red light in a light-emitting diode (LED) system. The device has an emission power of 100 milliwatts per square centimeter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL)
Description: The IPL therapy will be performed using the Eye-light® with Optimal Power Energy® (Espansione Marketing S.p.A., Bologna, Italy), which emits the light at a wavelength of 600 nm IPL system with fluence ranging from 10 to 16 J/cm2 per eye depending on the Fitzpatrick skin scale. During IPL treatment 5 flashes of light will be applied to the skin around the eye using a handheld device; 3 along the inferior orbital rim, 1 at the lateral canthus, and 1 applied horizontally along the inferior orbital rim

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intense pulsed light (IPL)
Description: The IPL therapy will be performed using the Eye-light® with Optimal Power Energy® (Espansione Marketing S.p.A., Bologna, Italy), which emits the light at a wavelength of 600 nm IPL system with fluence ranging from 10 to 16 J/cm2 per eye depending on the Fitzpatrick skin scale. During IPL treatment 5 flashes of light will be applied to the skin around the eye using a handheld device; 3 along the inferior orbital rim, 1 at the lateral canthus, and 1 applied horizontally along the inferior orbital rim
Study: NCT05682248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Transcranial magnetic stimulation
Description: Sham Transcranial magnetic stimulation
Study: NCT04912011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canrenoate Potassium
Description: Intervention: 200 mg of Canrenoate potassium in 100 ml 0,9% NaCl, intravenously twice a day for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo: 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
Study: NCT06083935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daflon
Description: Daflon; two film coated tablets 500 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daflon
Description: Daflon; two film coated tablets 500 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive
Description: Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined oral contraceptive
Description: Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined oral contraceptive
Description: Yassmin ® film-coated tablets 3 mg of drospirenone and 0.03 mg of ethinyl estradiol once daily daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Glucophage ® 500 tablets twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Glucophage ® 500 tablets twice daily
Study: NCT05571579

Intervention type: BIOLOGICAL
Intervention: blood and/or csf collection
Description: blood and/or collection~Only once :~* 1 tube of blood of 4 mL on dry tube with or without gel,~* 2 tubes of blood of 4 mL on EDTA tube, If CSF collected for diagnosis is available, it can be sent for storage in the collection.
Study: NCT06559241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 14-day remote ischemic conditioning
Description: RIC is a noninvasive therapy performed by an electric auto-control device with a cuff placed on the upper arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of the cuff on the upper arm. The procedure will be performed once before endovascular thrombectomy and twice daily for 14 days post-thrombectomy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30-day remote ischemic conditioning
Description: RIC is a noninvasive therapy performed by an electric auto-control device with a cuff placed on the upper arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of the cuff on the upper arm. The procedure will be performed once before endovascular thrombectomy and twice daily for 30 days post-thrombectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Description: Endovascular thrombectomy procedures are performed according to the guidelines to recanalize the occluded large vessel safely.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Description: Endovascular thrombectomy procedures are performed according to the guidelines to recanalize the occluded large vessel safely.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular thrombectomy
Description: Endovascular thrombectomy procedures are performed according to the guidelines to recanalize the occluded large vessel safely.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best medical management
Description: Best medical management is prescribed at the discretion of the treating physicians according to the guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best medical management
Description: Best medical management is prescribed at the discretion of the treating physicians according to the guidelines.

Intervention type: DRUG
Group type: OTHER
Intervention: Best medical management
Description: Best medical management is prescribed at the discretion of the treating physicians according to the guidelines.
Study: NCT04903093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib tablet
Description: Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F1
Description: Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.
Study: NCT06726889

Intervention type: BEHAVIORAL
Intervention: Standard care
Description: Patient will not receive any additional interventions

Intervention type: BEHAVIORAL
Intervention: Standard care
Description: Patient will not receive any additional interventions
Study: NCT05223829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexanolone
Description: Brexanolone will be administered as a continuous IV infusion over 20 hours under medical observation
Study: NCT05697757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Lighting
Description: This will be an eighteen-hour lighting scheme that includes three modes: morning (6:00 - 12:00), afternoon (12:00 - 18:00), and evening (18:00 - 24:00). It mimics natural lighting by providing blue-enriched high-intensity lighting in the morning and neutral white medium-intensity lighting in the afternoon to maintain alertness without exerting substantial circadian effects. The biodynamic lighting will provide yellowish low-intensity lighting in the evening to minimize any circadian effect.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Lighting
Description: This will be an eighteen-hour lighting scheme that includes three modes: morning (6:00 - 12:00), afternoon (12:00 - 18:00), and evening (18:00 - 24:00). It mimics natural lighting by providing blue-enriched high-intensity lighting in the morning and neutral white medium-intensity lighting in the afternoon to maintain alertness without exerting substantial circadian effects. The biodynamic lighting will provide yellowish low-intensity lighting in the evening to minimize any circadian effect.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Lighting
Description: We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness from morning to evening. The numbers of CCT and illuminance levels are selected based on the average room lighting
Study: NCT05586685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: effect of diaphragmatic release on upper crossed syndrome
Description: The patients will be positioned in the supine position. The therapist stood at the head of the patient.therapist make manual contact of ribs and ask patient to inspire the move ribs laterally and then expire~conventional exercise Subjects will form the letter 'Y' with their arms then they will flex their elbows and move into a position of shoulder extension, so that their arms will form the letter 'w L to Y Exercise: Subjects will begin with arms abducted to 90° and elbows flexed to 90° Chin tucks : Subjects will length the neck by pushing the chin into the table in an entirely posterior motion stretch pectoral area from supine lying position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: effect of diaphragmatic release on upper crossed syndrome
Description: The patients will be positioned in the supine position. The therapist stood at the head of the patient.therapist make manual contact of ribs and ask patient to inspire the move ribs laterally and then expire~conventional exercise Subjects will form the letter 'Y' with their arms then they will flex their elbows and move into a position of shoulder extension, so that their arms will form the letter 'w L to Y Exercise: Subjects will begin with arms abducted to 90° and elbows flexed to 90° Chin tucks : Subjects will length the neck by pushing the chin into the table in an entirely posterior motion stretch pectoral area from supine lying position
Study: NCT05697757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Lighting
Description: We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness from morning to evening. The numbers of CCT and illuminance levels are selected based on the average room lighting
Study: NCT06499961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital version of Holistic Healthy Life Education
Description: Participants need to attend a two-day workshop related to (1) health risk appraisal and self-care; (2) exercise, fitness and self-acupressure; (3) emotion and stress management; (4) the whole food plant-based (WFPB) diet; and (5) meditation and mindfulness practices, led by a multi-disciplinary team. Before the intervention commences, they will take pre-blood test and further receive the e2HLE with Hera Leto for three months. During the intervention, participants will attend (1) nine weekly workshops pertaining to WFPB diet, exercise, fitness and self-acupressure, and meditation and mindfulness and followed by weekly tele-counselling sessions; (2) three process evaluation practice sharing sessions in the format of focus group, making up a total of twelve sessions. The process evaluation practice sharing sessions will be audio-recorded; (3) mutual support networking platform will be held between case managers and participants within Hera Leto system.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist control
Description: usual care first, then switch to receive the intervention
Study: NCT05490472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-2485 (Aurora A inhibitor)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-2485 (Aurora A inhibitor)
Description: Administered orally
Study: NCT05465746

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour ambulatory blood pressure monitoring (ABPM)
Description: Using a WatchBPO3 AFIB device (Microlife) placed around the left upper arm, BP measurements will be recorded every twenty minutes during the day and every thirty minutes at night, over a twenty-four-hour period. The device will automatically calculate the BP and the twenty-four-hour average BP, day, night, and cumulative BP load

Intervention type: DIAGNOSTIC_TEST
Intervention: Three-dimensional transthoracic echocardiography
Description: Using an EPIQ CVx (Philips) echocardiograph with an ultrasound sector transducer, 3D-TTE will be performed to assess the LVM index.
Study: NCT06343389

Intervention type: DIAGNOSTIC_TEST
Intervention: serum creatinine
Description: to detect patients with Acute kidney injury
Study: NCT05147740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg fixed-dose combination administered orally once daily without regard to food.
Study: NCT06226467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurobehavioral Affective Control Training
Description: The N-ACT program comprises a series of eight training sessions, lasting one hour each, over two months. N-ACT sessions will be guided by a cognitive training coach (supervised by a licensed mental health clinician), who will explain intervention procedures and rationale, offer relevant psychoeducation, and use motivational interviewing principles to provide encouragement and support. In addition to coach-led content, participants will spend about half of each weekly training session (\~30 minutes) practicing two computer-based adaptive training tasks targeting affective control.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neurobehavioral Affective Control Training
Description: The N-ACT program comprises a series of eight training sessions, lasting one hour each, over two months. N-ACT sessions will be guided by a cognitive training coach (supervised by a licensed mental health clinician), who will explain intervention procedures and rationale, offer relevant psychoeducation, and use motivational interviewing principles to provide encouragement and support. In addition to coach-led content, participants will spend about half of each weekly training session (\~30 minutes) practicing two computer-based adaptive training tasks targeting affective control.
Study: NCT04974047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously as specified in the treatment arm.